AU2005279460A1 - Treatment of HIV infection by T-cell modulation - Google Patents

Treatment of HIV infection by T-cell modulation Download PDF

Info

Publication number
AU2005279460A1
AU2005279460A1 AU2005279460A AU2005279460A AU2005279460A1 AU 2005279460 A1 AU2005279460 A1 AU 2005279460A1 AU 2005279460 A AU2005279460 A AU 2005279460A AU 2005279460 A AU2005279460 A AU 2005279460A AU 2005279460 A1 AU2005279460 A1 AU 2005279460A1
Authority
AU
Australia
Prior art keywords
cell
hiv
cells
administering
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005279460A
Other languages
English (en)
Inventor
Werner Krause
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of AU2005279460A1 publication Critical patent/AU2005279460A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2005279460A 2004-08-30 2005-07-28 Treatment of HIV infection by T-cell modulation Abandoned AU2005279460A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60517304P 2004-08-30 2004-08-30
US60/605,173 2004-08-30
PCT/EP2005/008325 WO2006024354A1 (en) 2004-08-30 2005-07-28 Treatment of hiv infection by t-cell modulation

Publications (1)

Publication Number Publication Date
AU2005279460A1 true AU2005279460A1 (en) 2006-03-09

Family

ID=35079284

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005279460A Abandoned AU2005279460A1 (en) 2004-08-30 2005-07-28 Treatment of HIV infection by T-cell modulation

Country Status (14)

Country Link
US (1) US20060057620A1 (https=)
EP (1) EP1784217A1 (https=)
JP (1) JP2008511559A (https=)
KR (1) KR20070050934A (https=)
AU (1) AU2005279460A1 (https=)
BR (1) BRPI0514729A (https=)
CA (1) CA2570735A1 (https=)
IL (1) IL179856A (https=)
MX (1) MX2007002188A (https=)
NO (1) NO20071700L (https=)
RU (1) RU2393872C2 (https=)
TW (1) TW200626172A (https=)
WO (1) WO2006024354A1 (https=)
ZA (1) ZA200702654B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008829A1 (en) * 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5795572A (en) * 1993-05-25 1998-08-18 Bristol-Myers Squibb Company Monoclonal antibodies and FV specific for CD2 antigen
AU2265701A (en) * 1999-12-16 2001-06-25 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease
US20040147428A1 (en) * 2002-11-15 2004-07-29 Pluenneke John D. Methods of treatment using an inhibitor of epidermal growth factor receptor

Also Published As

Publication number Publication date
KR20070050934A (ko) 2007-05-16
US20060057620A1 (en) 2006-03-16
WO2006024354A1 (en) 2006-03-09
ZA200702654B (en) 2008-08-27
CA2570735A1 (en) 2006-03-09
NO20071700L (no) 2007-05-29
IL179856A0 (en) 2007-05-15
EP1784217A1 (en) 2007-05-16
TW200626172A (en) 2006-08-01
JP2008511559A (ja) 2008-04-17
BRPI0514729A (pt) 2008-06-24
RU2393872C2 (ru) 2010-07-10
IL179856A (en) 2010-11-30
MX2007002188A (es) 2007-10-16
RU2007111566A (ru) 2008-10-10

Similar Documents

Publication Publication Date Title
Margolis et al. HIV antibodies for treatment of HIV infection
CN109996815A (zh) 以cd4抗体于稳定接受haart治疗的患者进行hiv感染的治疗和持续性的病毒缓解
US6114312A (en) Method of inhibiting human immunodeficiency virus by combined use of hydroxyurea, a nucleoside analog, and a protease inhibitor
M Amedee et al. Chronic alcohol abuse and HIV disease progression: studies with the non-human primate model
Henderson Postexposure chemoprophylaxis for occupational exposure to human immunodeficiency virus type 1: current status and prospects for the future
JP2022514561A5 (https=)
US20060057620A1 (en) Treatment of HIV infection
AU2003299085B2 (en) Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome
US20080233128A1 (en) Treatment of Viral Infections
US20220016079A1 (en) Combination treatment of hiv infections
CN121511095A (zh) 治疗表达cd20的b细胞癌症的方法
US6251874B1 (en) Method of inhibiting human immunodeficiency virus using hydroxurea and a reverse transcriptase inhibitor in vivo
KR20170042706A (ko) 치료 대용법으로서의 ｈｉｖ 항체 요법
Acosta et al. Agents for treating human immunodeficiency virus infection
Karahalil et al. COVID-19: are experimental drugs a cure or cause?
Ugen et al. Injecting drugs of abuse and immunity: implications for HIV vaccine testing and efficacy
Vrendenbarg The Role of TLR7 and/or TLR8 Agonists in HIV Cure
WO1999048526A1 (en) METHOD OF RENDERING A HUMAN IMMUNODEFICIENCY VIRUS POPULATION REPLICATION INCOMPETENT $i(IN VIVO)
Cao et al. The Whole is Greater than the Sum of the Parts, Combination Use as CABENUVA in Treating HIV: Meta-Analysis from Clinical Datasets
AU703324B2 (en) Antibody-based treatment of HIV infection
WO2000045844A1 (en) Use of hydroxyurea and a reverse transcriptase inhibitor to induce autovaccination by autologous hiv
WO2025208443A1 (en) Methods of treatment warm autoimmune hemolytic anemia using sovleplenib
WO1999047146A1 (en) Anti-hiv combination comprising hydroxyurea, ddi, and a protease inhibitor
Gibaldi The eleventh international conference on AIDS: cautious celebration in Vancouver
Sinclair New paradigms in the history of highly active antiretroviral therapy for HIV-1 infection

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application